| AMGN |
Report |
2Q26 Revenue |
IN-LINE |
pred ~$9.46B vs. cons $9.426B |
MEDIUM |
| AMGN |
Report |
2Q26 Operating Diluted EPS |
BEAT |
pred ~$5.66 vs. cons $5.584 |
MEDIUM |
| AMGN |
Report |
2Q26 Repatha revenue |
BEAT |
pred ~$935M vs. cons $922M |
MEDIUM |
| AMGN |
Guide |
FY26 Revenue |
UNCHANGED |
guide $37.1B-$38.5B vs. cons $37.817B |
MEDIUM |
| AMGN |
Guide |
FY26 Non-GAAP EPS |
UNCHANGED |
guide $21.70-$23.10 vs. cons $22.36 |
MEDIUM |
| AMGN |
Guide |
FY26 Operating Margin / Denosumab Commentary |
UNCHANGED |
guide ~45%-46%; denosumab erosion as planned vs. cons UNVERIFIED |
LOW |
| AMGN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| AMGN |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH - maintained FY guidance implies modestly softer out-period math |
LOW |